Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer - ACCESS I

NCT06670911 is registered in ClinicalTrials.gov with Instituto Nacional de Cancer, Brazil as lead sponsor.

NCT NCT06670911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06670911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer - ACCESS I
Lead sponsor
Instituto Nacional de Cancer, Brazil
Phase
Phase 2
Overall status
Recruiting
Start date
February 20, 2025
Completion date
April 30, 2028
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

persistent, recurrent, or metastatic cervical cancer